| Product Name | MF | CAS | Details |
|---|
| Bupivacaine Impurity 16 | C10H19NO2 | 856838-98-7 | Details |
| Cefazolin EP Impurity G | C11H10N6O4S | 1172998-53-6 | Details |
| 7-ACA lactone Impurity 2 | C8H8N2O3S | 184696-69-3 | Details |
| Fulvestrant Impurity I | C17H12F3N3O4S | 170571-01-4 | Details |
| Canagliflozin Ring Opening Impurity | Details |
| Canagliflozin Furanose Impurity | Details |
| Canagliflozin alpha-Isomer Impurity | Details |
| Cefuroxime sodium Impurity F | C15H15N3O7S | 97170-19-9 | Details |
| Bupivacaine Impurity 4 | C18H28N2O | 2125995-25-5 | Details |
| Betaxolol Impurity 2 | C14H23NO3 | 131564-69-7 | Details |
| 3-(p-tolyl)-5-(trifluoromethyl)-1H-pyrazole | C11H9F3N2 | 219986-64-8 | Details |
| AZD9291（Osimertinib） Impurity 6 | Details |
| Betaxolol Impurity 4 | Details |
| cis-Hydroxy Loxoprofen & trans-Hydroxy Loxoprofen | Details |
| Azithromycin impurity A | C37H70N2O12 | 76801-85-9 | Details |
| AztreonaM IMpurity 1 | C4H8N2O4S | Details |
| Lactate tetramer | C17H14F3N3O2S | 331943-04-5 | Details |
| Canagliflozin Defluoro Impurity | Details |
| AZD9291（Osimertinib） Impurity 11 | Details |
| Clavulanic acid Impurity F | Details |
| Clavulanic acid Impurity A | C8H12N2O2 | 4744-51-8 | Details |
| Celecoxib Impurity 1 | C17H14F3N3O2S | 170570-01-1 | Details |
| Varenicline Impurity D | C17H14F3N3O2S | 170569-99-0 | Details |
| DL-Methionine Sulfoxide | C22H18N4O2S | 1347304-18-0 | Details |
| Canagliflozin Dimer Impurity 1 | Details |
| Carboplatin EP Impurity B | C6H8O4 | 5445-51-2 | Details |
| Bupivacaine Impurity 8 | C22H37N2O | 852804-30-9 | Details |
| AZD9291 Osimertinib Impurity 2 | Details |
| 2-hydroxy-11-(methylthio)butanamide | 247068-81-2 | Details |
| Cinacalcet impurity 33 | C10H11F3O | 180635-74-9 | Details |
| Candesartan Impurity 16 | C14H18N2O6 | 136285-65-9 | Details |
| Clavulanic acid Impurity B | C11H16N2O4 | 96681-85-5 | Details |
| Deubutafrazine Impurity | C13H13N5O5S2 | 71091-93-5 | Details |
| Cefuroxime sodium Impurity G | C17H17N3O8S | 97232-98-9 | Details |
| Bupivacaine Impurity 5 | C18H28N2O.ClH | 2125995-28-8 | Details |
| Betaxolol Impurity 3 | C14H23NO3 | 131564-70-0 | Details |
| AZD9291（Osimertinib） Impurity 7 | Details |
| Betaxolol Impurity 5 | Details |
| Clavulanic acid Impurity 1 | C6H8KNO4 | 2196185-67-6 | Details |
| Lactate tetramer | C13H10N2O7S | 28328-53-2 | Details |
| Baricitinib Impurity I | C21H28N2O5S | 32643-00-8 | Details |
| Clavulanic acid Impurity G | C13H15NO6 | Details |
| Betaxolol Impurity 1 | C14H23NO3 | 62572-94-5 | Details |
| Azithromycin impurity S | C38H70N2O13 | 53066-26-5 | Details |
| Deubutafrazine Impurity | C14H19N3O7S | 1476-46-6 | Details |
| Celecoxib iMpurity 5 | C11H9F3O2 | Details |
| Vitamin B6 Impurity 91 | C15H17N3O2S | 1061214-06-9 | Details |
| Cefazolin Impurity 10 | C10H12N2O5S | 18884-65-6 | Details |
| Celecoxib Impurity 16 | C9H10N2O | 92-43-3 | Details |
| Canagliflozin Monoacetyl Impurity | Details |
| AZD9291（Osimertinib） Impurity 4 | Details |
| AZD9291（Osimertinib） Impurity 9 | Details |
| Phthalamic Acid | C21H28N2O5S | 153012-65-8 | Details |
| Cefuroxime sodium Impurity D | C18H15Cl3N4O9S | 76598-06-6 | Details |
| Cefuroxime sodium Impurity E | C16H16N4O8S | 97232-97-8 | Details |
| Clavulanic acid Impurity J | C6H18Cl2N2 | 7677-21-6 | Details |
| Axitinib Impurit | C22H18N4O3S | 1348536-59-3 | Details |
| Dapagliflozin iMpurity 35 | C15H14Br2O | 1807632-93-4 | Details |
| Clavulanic acid Impurity 2 | C8H16O2 | 149-57-5 | Details |
| AZD9291 Osimertinib Impurity 3 | Details |
| Carfilzomib Impurity MV | Details |
| Celecoxib Impurity 10 | C11H9F3N2 | 948293-46-7 | Details |
| Cinacalcet impurity 32 | C10H11F3O | 191155-81-4 | Details |
| Cefazolin Impurity 11 | C8H10N2O4S | 15690-38-7 | Details |
| Clavulanic acid Impurity D | C7H9NO3 | 404839-11-8 | Details |
| Baricitinib Impurity I | C11H9F3N2 | 26974-15-2 | Details |
| 2-hydroxy-17-(methylthio)butanamide | C14H14ClN3O4S | 188915-50-6 | Details |
| Valsartan Methyl Ester | C18H16F3N3O2S | 170570-09-9 | Details |
| Bupivacaine Impurity 1 | C18H28N2O | 2125995-24-4 | Details |
| Bupivacaine Impurity 6 | C18H28N2O.ClH | 2125995-27-7 | Details |
| Axitinib Impurity 21 | Details |
| AZD9291（Osimertinib） Impurity 8 | Details |
| Canagliflozin Dimer Impurity 2 | Details |
| Ampicillin EP Impurity H | C10H8N2O | 2882-18-0 | Details |
| AztreonaM IMpurity D | Details |
| Cilnidipine Impurity 60 | C17H15F3N2O3S | 1061214-09-2 | Details |
| Bupivacaine Impurity 3 | C18H28N2O | 2125995-26-6 | Details |
| Axitinib Impurity 27 | C24H20N4O2S | 1639137-80-6 | Details |
| Celecoxib | C17H14F3N3O2S | 169590-42-5 | Details |
| Cefazolin Impurity 3 | C14H17N3O6S | 2429-86-9 | Details |
| N-(2-((2-acrylamido-5-methoxy-4 | Details |
| Azilsartan iMpurity Y | Details |
| Celecoxib Impurity 15 | C17H14F3N3O2S | Details |
| Cefaclor EP Impurity B | C7H7ClN2O3S | 53994-69-7 | Details |
| Valsartan Methyl Ester | C13H12N2O5S | 28328-54-3 | Details |
| Celecoxib Impurity 4 | C16H12F3N3O2S | 170569-87-6 | Details |
| Citalopram Impurity 1 | C18H17FN2O | 62498-69-5 | Details |
| Clavulanic acid Impurity E | Details |
| AZD9291（Osimertinib） Impurity 10 | Details |
| Carfilzomib Impurity MX | Details |
| Cefoxitin EP Impurity G | Details |
| Clavulanic acid Impurity C | C10H16N2O2 | 86917-74-0 | Details |
| Belinostat Impurity A | C15H14N2O4S | 1884227-58-0 | Details |
| Celecoxib Impurity 8 | C8H8F3N3O3S | 915280-81-8 | Details |
| Bupivacaine Impurity 2 | C18H28N2O | 2125994-25-2 | Details |
| Bupivacaine Impurity 9 | C22H37N2O.I | 852669-91-1 | Details |
| Bumetanide Aminobenzoic Acid | C17H20N2O5S | 28395-03-1 | Details |
| Axitinib Impurity 22 | Details |
| AZD9291 Osimertinib Impurity 1 | Details |
| Carboplatin Impurity 2 | Details |
| Product Total： Product Page： | ||||
| 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 | ||||